GlassScriptPhysician profile
Angeline G Walker
NPI 1760050413
$5,459.22
in general payments reported to CMS, 2019-2025
25 companies · $1,201 in 2025
The $1,201 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.47 · 2022: $362 · 2023: $1,944 · 2024: $1,939 · 2025: $1,201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,056 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,056.26 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $676.33 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $635.78 | 2022-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $584.07 | 2022-2025 | Uzedy, Austedo, Austedo Xr |
| Alkermes, INC. | $568.26 | 2022-2025 | Aristada, Lybalvi, Aristada Initio |
| Janssen Pharmaceuticals, INC | $521.44 | 2022-2025 | Invega Sustenna, Spravato, Invega |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $504.10 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $375.47 | 2022-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Lundbeck LLC | $324.87 | 2022-2025 | Rexulti, Brintellix |
| Axsome Therapeutics, INC. | $287.85 | 2023-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $279.85 | 2022-2025 | Fanapt, Hetlioz |
| Indivior INC. | $115.17 | 2022-2024 | Perseris, Sublocade |
| Takeda Pharmaceuticals U.S.A., INC. | $107.77 | 2023-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $100.66 | 2024-2025 | Cobenfy |
| Tempus Ai, INC | $66.77 | 2024 | |
| Sunovion Pharmaceuticals INC. | $62.08 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $51.38 | 2022-2023 | Jornay Pm |
| Sage Therapeutics, LLC | $37.79 | 2025 | Zurzuvae |
| Bausch Health US, LLC | $36.28 | 2023-2025 | Aplenzin, Wellbutrin |
| Corium, LLC | $23.03 | 2024 | Azstarys |
| Avanir Pharmaceuticals, INC. | $19.00 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.97 | 2024 | Rexulti |
| Janssen Scientific Affairs, LLC | $17.64 | 2025 | Invega Sustenna |
| Noven Therapeutics, LLC | $15.86 | 2024 | Xelstrym, Secuado |
| Idorsia Pharmaceuticals US INC | $15.33 | 2023 | Quviviq |
| Bioventus LLC | $13.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angeline Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.